Description of Research Expertise:
lymphocyte biology, with a major translational focus on ex vivo T-cell engineering for cancer and HIV cell based therapies.
Key words: T cells, human, gene therapy, genetic engineering, signal transduction.
Description of Research
The June Lab is primarily responsible for developing new CARs and new vectors for current and proposed indications. This lab also fosters the development of Penn students both in doctoral and post-doctoral programs. The June Laboratory provides researchers with the tools they need to translate laboratory insights into safe and effective cancer therapies. The June Laboratory works with University of Pennsylvania faculty members interested in moving biologically-focused research ideas into clinical trials. In addition, the June Laboratory has a cadre of faculty researchers focused on developing ways to enhance the ability of the natural immune system to recognize and eliminate tumor cells. Translational research is a core unit of the The Leonard and Madlyn Abramson Family Cancer Research Institute at the Abramson Cancer Center at the University of Pennsylvania. Created in December 1997 with a $100 million pledge from the Abramson Family Foundation, the Cancer Research Institute integrates research, education, and comprehensive patient care at the Abramson Cancer Center at the University of Pennsylvania. For more information, see the Translational Research Mission Statement.
Keisuke Watanabe, Ph.D.
Christopher Kloss, Ph.D.
Mauro Castellarin, Ph.D.
Biliang Hu, Ph.D.
Decheng "DC" Song
John Scholler, Staff Scientist
Porter David L, Levine Bruce L, Kalos Michael, Bagg Adam, June Carl H: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England journal of medicine 365 (8): 725-33,2011.
Kalos Michael, Levine Bruce L, Porter David L, Katz Sharyn, Grupp Stephan A, Bagg Adam, June Carl H: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced Leukemia. Science translational medicine 3 (95): 95ra73,2011.
Rapoport Aaron P, Aqui Nicole A, Stadtmauer Edward A, Vogl Dan T, Fang Hong-Bin, Cai Ling, Janofsky Stephen, Chew Anne, Storek Jan, Akpek Gorgun, Badros Ashraf, Yanovich Saul, Tan Ming T, Veloso Elizabeth, Pasetti Marcela F, Cross Alan, Philip Sunita, Murphy Heather, Bhagat Rita, Zheng Zhaohui, Milliron Todd, Cotte Julio, Cannon Andrea, Levine Bruce L, Vonderheide Robert H, June Carl H: Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117 (3): 788-97,2011.
Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH.: Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 7 : 808-16,2008.
Paulos Chrystal M, Carpenito Carmine, Plesa Gabriela, Suhoski Megan M, Varela-Rohena Angel, Golovina Tatiana N, Carroll Richard G, Riley James L, June Carl H: The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Science translational medicine 2 (55): 55ra78,2010.
Gattinoni Luca, Lugli Enrico, Ji Yun, Pos Zoltan, Paulos Chrystal M, Quigley Máire F, Almeida Jorge R, Gostick Emma, Yu Zhiya, Carpenito Carmine, Wang Ena, Douek Daniel C, Price David A, June Carl H, Marincola Francesco M, Roederer Mario, Restifo Nicholas P: A human memory T cell subset with stem cell-like properties. Nature medicine 17 (10): 1290-7,2011.
June CH, Blazar BR, Riley JL: Engineering lymphocyte subsets: tools, trials and tribulations. Nature Reviews Immunology 9 (10): 704-16,2009.
Carpenito Carmine, Milone Michael C, Hassan Raffit, Simonet Jacqueline C, Lakhal Mehdi, Suhoski Megan M, Varela-Rohena Angel, Haines Kathleen M, Heitjan Daniel F, Albelda Steven M, Carroll Richard G, Riley James L, Pastan Ira, June Carl H: Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America 106 (9): 3360-5,2009.
Riley James L, June Carl H, Blazar Bruce R: Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30 (5): 656-65,2009.
Paulos CM, June CH: Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. Journal of Clinical Investigation 120 (1): 76-80,2010.
View all publications